H.C. Wainwright reiterates Ultragenyx stock rating on PRV sale
H.C. Wainwright reiterated a Buy rating and $25 price target on Ultragenyx (RARE) after its sale of a priority review voucher for $210M. The company's stock is down 52% over the past year. Ultragenyx also received FDA approval for FAYUVI, its gene therapy for Sanfilippo syndrome Type A, marking its second gene therapy approval.
How this was made
The 30-second read
Why it matters
The voucher sale provides immediate liquidity, while the FDA approval strengthens long‑term growth prospects, creating a dual catalyst for the stock.
Market read
A $210 M voucher sale combined with recent FDA approval offers a fresh catalyst for RARE, likely prompting short‑term buying interest.
What to watch
Potential antitrust waiting period and regulatory scrutiny could delay closing, reducing immediate upside.
Background
Ultragenyx recently received FDA approval for its gene therapy FAYUVI, marking its second approved therapy and improving its pipeline credibility.
Ticker impact
Ultragenyx Pharma announced a definitive agreement to sell a Rare Pediatric Disease priority review voucher for $210 million, providing a significant cash infusion.
likely upside as investors price in the $210 M cash infusion and reduced liquidity risk
Large one‑time cash receipt for a micro‑cap biotech typically triggers buying pressure, especially after a recent FDA approval.
Market effects
The voucher sale highlights growing demand for priority review vouchers in the rare‑disease biotech sector, potentially boosting valuations of peers with similar assets.
US biotech market may see modest uplift as cash‑rich micro‑caps attract attention.
Limited to biotech investors; no broad market impact.
Counterpoint
The cash may be a one‑off event; underlying cash‑burn remains high, so the stock could face pressure once the infusion is spent.
Key entities
- companyUltragenyx Pharma
Biotech firm focused on rare pediatric diseases (ticker RARE).
- analystH.C. Wainwright
Equity research firm reiterating a Buy rating and $25 price target.
